<DOC>
	<DOCNO>NCT00404521</DOCNO>
	<brief_summary>Phase I single-institution , open-label , dose-escalating , clinical pharmacokinetic study . The purpose determine safety , tolerability identify dose limit toxicity ( DLT ) recommend dose ( RD ) PM02734 administer every 3 week , intravenously , 30 minute subject advance malignant solid tumor .</brief_summary>
	<brief_title>A Phase I Study PM02734 Subjects With Advanced Malignant Solid Tumors</brief_title>
	<detailed_description>Phase I single-institution , open-label , dose-escalating , clinical pharmacokinetic study . The purpose determine safety , tolerability identify dose limit toxicity ( DLT ) recommend dose ( RD ) PM02734 administer every 3 week , intravenously , 30 minute subject advance malignant solid tumor . Secondary objective determine preliminary Pharmacokinetics PM02734 , explore relationship pharmacokinetics pharmacodynamics . To evaluate preliminary pharmacokinetics/pharmacodynamics correlation evaluate preliminary antitumor activity PM02734 . The trial conduct compliance protocol , GCP applicable regulatory requirement .</detailed_description>
	<criteria>1 . Voluntary write informed consent subject obtain studyspecific procedure . 2 . Histologically cytologically confirm malignant solid tumor . 3 . Subjects malignancies standard therapy would reasonably expect result cure palliation . 4 . Age ≥ 18 year . 5 . Subject measurable nonmeasurable disease use RECIST criterion ( subject measurable disease allow enter expand cohort ) . 6 . Recovery drugrelated adverse event derive previous treatment , exclude alopecia NCICTCAE grade 1 symptomatic peripheral neuropathy . 7 . Laboratory value within 7 day prior first infusion : Platelet count ≥ 100 x109/L , hemoglobin &gt; 9 g/dL absolute neutrophil count ( ANC ) ≥ 1.5 x109/L . Alkaline phosphatase ≤ 2.5 x upper limit normality ( ULN ) ( &lt; 5 x ULN case extensive bone metastasis ) . Aspartate aminotransferase ( AST ) : ≤ 2.5 x ULN ( &lt; 5 x ULN case extensive liver metastasis ) . Alanine aminotransferase ( ALT ) : ≤ 2.5 x ULN ( &lt; 5 x ULN case extensive liver metastasis ) . Total bilirubin:1.5 ≤ ULN , unless due Gilbert 's syndrome . Creatinine : ≤ ULN , measure creatinine clearance : ≥ 60 mL/min without significant proteinuria ( &gt; 250 mg/m2 /day ) Albumin ≥ 2.5 g/dL . Partial thromboplastin time ≤ 1.1 x ULN INR ≤ 1.1 8 . Performance status ( ECOG ) ≤ 2 . 9 . Life expectancy ≥ 3 month . 10 . Left ventricular ejection fraction ( LVEF ) within normal limit . 11 . Women childbearing potential must negative serum pregnancy test study entry . Both men woman must agree use medically acceptable method contraception throughout treatment period 3 month discontinuation treatment . Acceptable method contraception include complete abstinence , IUD , oral contraceptive , subdermal implant double barrier ( condom contraceptive sponge contraceptive suppository ) . 1 . Prior therapy PM02734 . 2 . Pregnant lactating woman . 3 . Less 4 week radiation therapy ( 8 week case extensive prior radiotherapy ) last dose hormonal therapy , biological therapy chemotherapy ( 6 week case nitrosourea , mitomycin C , highdose chemotherapy ) . 4 . Evidence progressive CNS metastasis symptomatic brain leptomeningeal metastasis . 5 . Evidence extensive liver metastasis ( 5 hepatic nodule great 5 cm diameter ) 6 . Other relevant disease adverse clinical condition : Increased cardiac risk : congestive heart failure unstable angor pectoris arrhythmia require treatment uncontrolled arterial hypertension myocardial infarction within 12 month inclusion study . History significant neurological psychiatric disorder . Active infection . Significant nonneoplastic liver disease ( e.g. , cirrhosis , active chronic hepatitis ) . Significant nonneoplastic renal disease . Immunocompromised subject , include subject know infected human immunodeficiency virus ( HIV ) . Uncontrolled endocrine disease ( e.g . diabetes mellitus , hypothyroidism hyperthyroidism , adrenal disorder ) ( i.e . require relevant change medication within last month hospital admission within last 3 month ) . Any major illness , investigator 's judgment , substantially increase risk associate subject 's participation study . 7 . Limitation subject 's ability comply treatment followup participate protocol . Subjects register trial must treat follow participate center . 8 . Treatment ongoing anticoagulation . 9 . Treatment investigational product 30 day period prior first infusion . 10 . Known hypersensitivity component drug product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Tumor</keyword>
	<keyword>PM02734</keyword>
	<keyword>PharmaMar</keyword>
</DOC>